Skip to main content
Triangle logo TriangleGet started

Biospecimen Collection (NCT06029270)

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer: a one-minute explainerNCT060292701 min

Biospecimen Collection trial for Metastatic Nasopharyngeal Carcinoma (NCT06029270). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with EBV-associated recurrent or metastatic nasopharyngeal cancer, without prior palliative systemic treatment. Local recurrence must be unsuitable for curative surgery or re-irradiation.

The idea: first give platinum, gemcitabine and nivolumab. Patients without progression are then randomized to nivolumab alone or with relatlimab. These antibodies target PD-1 and LAG-3 immune brakes. Maintenance infusions repeat every four weeks for up to two years.

This phase 2 study plans 156 patients. Brigette Ma leads the NCI-sponsored trial, with 78 recruiting US sites.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.